课题基金 / 基金详情

Molecular mechanisms of human cytochrome P450 CYP3A4 gene regulation

Molecular mechanisms of human cytochrome P450 CYP3A4 gene regulation
人细胞色素P450 CYP3A4基因调控的分子机制
批准号:
nhmrc : 107245
负责人:
Prof Christopher Liddle
金额:
$13.07万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2000
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2000-01-01 至 2002-12-31

项目摘要

项目成果

Prof Christopher Liddle的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Liver cytochrome P450 enzymes are important to medicine in areas as broad as drug breakdown, steroid hormone regulation and the formation or elimination of cancer causing chemicals. These enzymes are present in high concentration in the human liver, but the factors governing how much of these enzymes are produced have been poorly understood. Cytochrome P450 3A4 (CYP3A4) is arguably the single most important factor is how humans handle therapeutic drugs. It has been estimated that over 60% of all drugs presently on the market are broken down, either in full or in part, by this enzyme. The amounts of CYP3A4 expressed in the liver differs markedly between individuals, and explains a great deal of the large variation in the way people break down drugs. Also, variations in the levels of CYP3A4 in the liver may be an important factor in both prostate cancer (the most common cancer in men) and the risk of developing leukemia after receiving chemotherapy for other cancers. The present projects builds on discoveries concerning the regulation of cytochrome P450 enzymes made by our group over the last few years, including an in-depth understanding of the way the production of CYP3A4 is increased by some drugs. In this project we seek to understand why individuals differ so much in terms of the amount of CYP3A4 in the liver (up to 10-fold) and why this enzyme is predominantly expressed in the liver and to as lesser extent, the intestine, while not being found at all in many other tissues. An understanding of these issues will allow us to: Y predict how patients will respond to drugs (pharmacogenetic testing). Y determine susceptibility to certain diseases (e.g., prostate cancer). Y develop novel drugs that can influence CYP3A4 production in the liver
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis
  • 批准号:
    nhmrc : GNT1107178
  • 项目类别:
    Project Grants
  • 资助金额:
    $87.1万
  • 财政年份:
    2016
  • 负责人:
    Prof Christopher Liddle
  • 依托单位:
MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis
  • 批准号:
    nhmrc : 1107178
  • 项目类别:
    Project Grants
  • 资助金额:
    $59.92万
  • 财政年份:
    2016
  • 负责人:
    Prof Christopher Liddle
  • 依托单位:
How does dietary cholesterol induce non-alcoholic steatohepatitis?
  • 批准号:
    nhmrc : 1108422
  • 项目类别:
    Project Grants
  • 资助金额:
    $55.23万
  • 财政年份:
    2016
  • 负责人:
    Prof Christopher Liddle
  • 依托单位:
Bile acid detoxification by nuclear receptor-mediated CYP3A regulation
  • 批准号:
    nhmrc : 153890
  • 项目类别:
    NHMRC Project Grants
  • 资助金额:
    $13.1万
  • 财政年份:
    2001
  • 负责人:
    Prof Christopher Liddle
  • 依托单位:
国内基金
海外基金
Exploring the Intrinsic Mechanisms of CEO Turnover and Market
  • 批准号:
    --
  • 项目类别:
    外国学者研究基金
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    HAOFEI Z
  • 依托单位:
Exploring the Intrinsic Mechanisms of CEO Turnover and Market Reaction: An Explanation Based on Information Asymmetry
  • 批准号:
    W2433169
  • 项目类别:
    外国学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    HAOFEI ZHANG
  • 依托单位:
Erk1/2/CREB/BDNF通路在CSF1R相关性白质脑病致病机制中的作用研究
  • 批准号:
    82371255
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    曹立
  • 依托单位:
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
  • 批准号:
    82370979
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张善勇
  • 依托单位: